



Bell Potter Healthcare Conference

26 November 2020



Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements” within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled ‘Risk factors’ in Imricor’s prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.



A pioneer and global leader in developing MRI-guided cardiac ablation products

Imricor is an innovative US based medical device company and is the only company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market





Heart arrhythmias and conventional treatment options

In the absence of MRI-compatible catheter ablation devices, physicians have been unable to take advantage of the potential benefits related to MRI guided ablation procedures for treating arrhythmias

Arrhythmias



- An arrhythmia is an abnormal heart rhythm



- Certain untreated arrhythmias can lead to serious cardiac conditions, such as blood clotting, stroke and/or death



- Rising global incidence of arrhythmias driven by secular demographic trends, such as aging population and increased occurrence of hypertension, obesity and diabetes

Conventional Treatment Options



- Conventional catheter ablation procedures performed guided by x-ray and aided by 3D mapping and tracking tools



- Antiarrhythmic drugs which focus on changing the electrical properties of cardiac tissue




- Implantable devices such as a pacemaker or defibrillator



The problems we are trying to solve through MRI guided ablation procedures



Visualisation



Procedure effectiveness



Cost



Procedure time



Safety

Existing Challenges

- Poor visualisation
- Permanency of lesions not determined

- Negative impact on single procedures success rates
- Vary from 38% to over 95%

- Repeat procedures result in higher medical costs

- Conventional 3D mapping systems add procedure time
- AFL ablation procedure 88 minute on average

- Radiation exposure during x-ray guided ablations
- Protective garments worn can lead to occupational injuries

Imricor's Solution

- Real-time imaging gives visibility to soft tissue and non-permanent lesions
- 2D and 3D imaging available

- Reduced likelihood of a repeat procedure
- 100% success rate for AFL procedures¹

- Increased effectiveness, fewer procedures and lower overall treatment cost

- Average procedure time for MRI-guided AFL ablations is 48 minutes
- Enables the physician to perform more procedures


- MRI generates no radiation removing the risk of radiation and need for heavy protective garments

¹ Imricor's clinical trial delivered a 100% chronic success rate for AFL procedures



Our business model

Today Imricor primarily generates revenue from the sale of its capital equipment and consumable products





A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

Drivers of Global Catheter Ablation Market



- Increased incidence of cardiac disease




- Shift towards minimally invasive procedures



- Cost effectiveness of catheter ablation as treatment option

EU¹ and US Cardiac Ablation Market



Sources:

Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020

Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

1. EU represented by five countries: UK, Germany, France, Spain, Italy




Core strategies to drive future growth

Imricor's strategy is focused on the two drivers that are key to revenue growth – the number of iCMR labs and the number of procedures performed using Imricor's consumables in each lab



Go to market strategies

- Collaborative sales distribution agreement with Philips
- Strategic relationship with Siemens
- Growing awareness through sales and marketing activities
- Engagement with Key Opinion Leaders
- Comprehensive training and support at clinical sites



Geographic expansion

- CE mark approval enables the sale of products in the EU
- Strategy to obtain FDA approval in the US well advanced and targeting clinical trials in 2021-2022
- Local agent to be selected to support TGA approval in Australia



Expanded indications

- Ablation catheter has CE mark approval for the treatment of atrial flutter
- Atrial flutter comprises only 23% of ablation procedures in the EU
- Planning to commence clinical trials to expand CE mark approval to other indications in 2021



Expanded Product Range

- Diagnostic catheter under development to support margin improvement
- Steerable sheath and transeptal needle supporting expanded indications
- NIH contract to develop a device to biopsy the inner walls of the heart guided by MRI
- Other opportunities beyond cardiac ablation



What to learn more about Imricor?



Transforming Cardiac Ablation Procedures

Imricor corporate procedural video

<https://vimeo.com/438663377>



Experience the Future of Cardiac Ablation

Dr. Thomas Gaspar and Dr. Stefan Ulbrich from the Dresden Heart Centre discuss their successes performing cardiac ablation utilising real-time MR imaging

<https://www.youtube.com/watch?v=qjXiMWuuvDI>



Early Results and Experiences for iCMR in Atrial Flutter

Jakob Tomala, Heart Centre Dresden

Ablation Center of the Future

Ivo Van Der Bilt, Haga Hospital

<https://www.magnetomworld.siemens-healthineers.com/magnetom-world-summit/recordings>



Contact information

Investors:

Steve Wedan
Executive Chair, President & CEO
Email: steve.wedan@imricor.com

Carrie Barrack
Cato & Clive
Email: carrie@catoandclive.com

Website:

<https://imricor.com/>

Follow us:

